Insider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) Insider Sells 18,000 Shares of Stock

G1 Therapeutics, Inc. (NASDAQ:GTHXGet Rating) insider Rajesh Malik sold 18,000 shares of G1 Therapeutics stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $15.71, for a total value of $282,780.00. Following the completion of the sale, the insider now owns 73,207 shares of the company’s stock, valued at $1,150,081.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

G1 Therapeutics Stock Down 1.6 %

Shares of NASDAQ:GTHX opened at $15.21 on Friday. The stock has a market cap of $650.23 million, a price-to-earnings ratio of -3.79 and a beta of 1.93. The company has a quick ratio of 4.38, a current ratio of 4.75 and a debt-to-equity ratio of 1.15. G1 Therapeutics, Inc. has a 12-month low of $3.84 and a 12-month high of $17.49. The business’s 50 day moving average is $11.76 and its 200 day moving average is $8.22.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.12. The company had revenue of $10.57 million for the quarter, compared to analysts’ expectations of $9.00 million. G1 Therapeutics had a negative return on equity of 140.17% and a negative net margin of 608.36%. On average, sell-side analysts forecast that G1 Therapeutics, Inc. will post -3.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Federated Hermes Inc. boosted its position in G1 Therapeutics by 353.2% in the second quarter. Federated Hermes Inc. now owns 179,472 shares of the company’s stock worth $887,000 after purchasing an additional 139,872 shares during the last quarter. Centiva Capital LP purchased a new position in G1 Therapeutics in the second quarter worth $58,000. Woodline Partners LP purchased a new position in G1 Therapeutics in the second quarter worth $8,878,000. PDT Partners LLC purchased a new position in G1 Therapeutics in the second quarter worth $393,000. Finally, Cubist Systematic Strategies LLC boosted its position in G1 Therapeutics by 91.7% in the second quarter. Cubist Systematic Strategies LLC now owns 257,912 shares of the company’s stock worth $1,274,000 after purchasing an additional 123,346 shares during the last quarter. Hedge funds and other institutional investors own 46.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GTHX shares. HC Wainwright reiterated a “buy” rating and issued a $67.00 target price on shares of G1 Therapeutics in a report on Friday, June 3rd. Needham & Company LLC decreased their price objective on G1 Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a report on Thursday, August 4th. Finally, Wedbush boosted their price objective on G1 Therapeutics from $20.00 to $25.00 and gave the company an “outperform” rating in a report on Friday. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.83.

G1 Therapeutics Company Profile

(Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Featured Articles

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.